投资者有时间到2026年4月13日, 加入对 uniQure 误导性的FDA 批准要求和数据拒绝后股票下跌的诉讼. Investors have until April 13, 2026, to join a lawsuit over uniQure’s misleading FDA approval claims and stock drop after data rejection.

2026年4月13日之前,uniQure N.V.(QURE)的投资者必须申请成为证券集团诉讼案的主要原告。 Investors in uniQure N.V. (QURE) have until April 13, 2026, to apply to become lead plaintiff in a securities class action lawsuit. 该诉讼涉及关于2025年9月24日至10月31日期间误导性披露的指控,声称该公司歪曲林业发展局核准其AMT-130试验设计,并低估了生物许可证申请时限的风险。 The suit, filed over allegations of misleading disclosures from September 24 to October 31, 2025, claims the company misrepresented the FDA’s approval of its AMT-130 trial design and downplayed risks to its Biologics License Application timeline. 2025年11月3日, 尼古尔(uniQure)透露, 林业发展局不再接受第一/二阶段的BLA支持试验数据, 导致库存下降49.33%。 On November 3, 2025, uniQure revealed the FDA no longer accepted its Phase I/II trial data for BLA support, triggering a 49.33% stock drop. 受影响的投资者可能有资格收回损失。 Affected investors may be eligible to recover losses.